GNI Group Ltd. (GNIIF)

OTCMKTS · Delayed Price · Currency is USD
15.50
0.00 (0.00%)
Mar 26, 2026, 4:00 PM EST
Market Cap1.13B +0.4%
Revenue (ttm)171.19M +13.7%
Net Income-28.13M
EPS-0.54
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume138
Open15.50
Previous Close15.50
Day's Range15.50 - 15.50
52-Week Range12.02 - 19.11
Beta1.37
RSIn/a
Earnings DateMay 15, 2026

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 867
Stock Exchange OTCMKTS
Ticker Symbol GNIIF

Financial Performance

Financial numbers in JPY Financial Statements